about
Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYSProfessional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problemsSummary of information on human CYP enzymes: human P450 metabolism data.Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications.Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin useStatin-induced myopathy: the two faces of Janus.Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathwaysCerivastatin-induced rhabdomyolysis: 11 case reports.Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review.Fluvastatin.Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.The rational use of potentially hepatotoxic medications in patients with underlying liver disease.Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.COX-2 selective inhibitors: analysis of the renal effects.The toxicology of HMG-CoA reductase inhibitors: prediction of human risk.Pharmacologic treatment of type 2 diabetic dyslipidemia.Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.The Impact of Exercise on Statin-Associated Skeletal Muscle Myopathy.Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood.New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination.Statins may aggravate myasthenia gravis.Molecular basis for statin-induced muscle toxicity: implications and possibilities.Rhabdomyolysis in a patient taking nebivolol.A Peculiar Formula of Essential Amino Acids Prevents Rosuvastatin Myopathy in Mice.Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety.Support of drug therapy using functional foods and dietary supplements: focus on statin therapy.Towards companion diagnostics for the management of statin therapy.Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Statins and the neuromuscular system: a neurologist's perspective.Interventions for Extracranial Carotid Artery Stenosis: An Update.Rhabdomyolysis in the setting of induced hypothyroidism and statin therapy: a case report
P2860
Q24320093-22F6C0C1-8640-4696-B36A-B37425E56451Q24679253-733E7A1F-75FF-4D6F-8983-7FBEB4FFA321Q32103802-28105B94-4A89-404A-A33E-A5CA4E38556FQ33148996-19DCAFBE-C73C-41AB-AE88-9E52EE44C965Q33937142-A7F9F453-1747-49DF-930C-9E4E709F591BQ34155702-FC416142-E423-4582-AF2D-5E6D7A420D2BQ34527445-1199B55B-D342-4346-BFD7-FFB97CD76E42Q34554637-76608597-E735-40CB-A1AF-3AB1ECEDEE9AQ34578989-2063304A-1201-4F35-8E7F-C40B33E9A500Q34592173-AE2FEF68-E21B-4D84-B96D-19DFC1C1D5D1Q34953788-1FD6A4CF-1644-4190-85E0-0785F547BB74Q35000978-018A0149-8E8E-4D9F-8956-421BB0069D5AQ35045471-C2576793-D49A-4C0E-9E0A-7BA301048926Q35194386-7B817FE8-3C77-48FE-AFA5-96F40C2FAA1DQ35194515-18F4308C-74CD-4AD3-A056-9DD29AB53C96Q35194523-CB7B4641-463F-4955-8C27-3026425969B2Q35194538-525ADA52-A2D3-488C-A6C9-F4E7295C5B2CQ35927194-008891F9-CD8A-4A0E-8DD3-51482C083002Q35976827-D990FB46-257A-4750-B3F4-1D8B73A96926Q36081978-122F1C85-FDFA-4691-889E-48EF9E2F7648Q36218752-5F74844B-017C-4073-94C5-17D602FD6CB5Q36288839-439B067C-D2A5-4063-8E1A-4DB791970BCCQ36569771-956AD1B6-A42B-4498-AB73-352E14442952Q36801821-15B41BCA-F876-46D5-A8BC-3DB57C770B1BQ36923822-E822E88A-F4B9-44D2-ADFC-2C3046452A9DQ37071188-D819B20F-4C12-4088-8189-C015342D9311Q37162015-079FBEC6-0A88-4A14-9924-BAF47D6C5C03Q37235648-F09EAF39-17C0-4D49-BEF5-36ECB3C95B00Q37260171-BCAE9902-BFD5-4313-B05A-13D448532F8CQ37341027-8F646B30-2409-43AE-8DFE-0AA9EC27D962Q37473376-C62F7D2B-DF92-4623-A9E2-B335C2296FA5Q37473382-573C187B-EDE7-4C05-A83F-9C9F4B0D23A7Q37578459-E0565CAE-D109-4EA3-ADF9-2EA5A23EBE94Q37701534-CAAC9597-8B3A-4EC5-A433-F74A1D537C9FQ38089842-3697E46C-CAE4-470A-8D53-3A357C0FC36FQ38092053-3AD43B61-FD21-414A-A8C1-2B5B66783B4CQ38109095-31FF78CA-472B-4071-BE86-4F27AC4CA180Q38286231-C37F5E01-4D8D-440B-B4F4-F06888485495Q38772425-2E32C6C4-E09E-4CCE-AC2A-EB18908EDBF6Q39835458-7BF88F77-6310-49F1-B92C-6CFC5AFE8FE3
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
HMG-CoA reductase inhibitors and myotoxicity.
@ast
HMG-CoA reductase inhibitors and myotoxicity.
@en
type
label
HMG-CoA reductase inhibitors and myotoxicity.
@ast
HMG-CoA reductase inhibitors and myotoxicity.
@en
prefLabel
HMG-CoA reductase inhibitors and myotoxicity.
@ast
HMG-CoA reductase inhibitors and myotoxicity.
@en
P2093
P1433
P1476
HMG-CoA reductase inhibitors and myotoxicity.
@en
P2093
P304
P356
10.2165/00002018-200022060-00003
P577
2000-06-01T00:00:00Z
P6179
1039668089